Ongoing Clinical Studies in Bladder Cancer
Cretostimogene grenadenorepvec (CG0070) is currently being evaluated in multiple studies including Phase 1b/2, Phase 2, and Phase 3 studies in the U.S. in BCG unresponsive NMIBC and MIBC. Two studies are actively recruiting. Studies are on-going in South Korea, Japan, China, Taiwan, Australia, and Canada.
TRIAL TITLE
TRIAL NUMBER
STAGE
STATUS
PUBLICATION
BOND-002
Safety and Efficacy
Phase 2, US only
Completed
BOND-003
Phase 3
Phase 3, Global (US, Japan, South Korea, Taiwan, Australia, Canada)
CORE-001
Phase 2, CG0070 Combined With Pembrolizumab
Phase 2, Global (US, South Korea)
Active, Not Recruiting
CORE-002
Phase 1 Study With Nivolumab Ineligible Cisplatin with MIBC
Phase 1b/2, US Only
Recruiting
Patients and Urologists interested in participating should contact:
JoAnn Horn
phone: 516-456-1415
joann.horn@CGOncology.com.
Partners
CG Oncology is eager to partner with companies who share our passion for improving patients and their loved one’s lives. Collaborations could be in R&D, business development or clinical trials. Our partners include:
- Merck
- Bristol Myers Squibb
- Roche
- Kissei Pharmaceutical Co.
- LEPU Medical Holdings
- FUJIFILM Diosynth Biotechnologies
If you are interested in becoming a partner with us, please contact us at bd@cgoncology.com
